Form 4: Centessa Legal Officer Sells Shares, Gains New Equity Awards

Centessa Pharmaceuticals' Chief Legal Officer, Iqbal J. Hussain, reported sales of ordinary shares while also receiving significant new restricted share units and stock options.

Summary

• Iqbal J. Hussain, Chief Legal Officer of Centessa Pharmaceuticals plc, reported several transactions involving the company's ordinary shares and derivative securities.
• Hussain sold a total of 39,961 ordinary shares across two transactions on January 30, 2026, and February 2, 2026, at weighted average prices of $25.0109 and $25.151, respectively.
• On February 1, 2026, 7,780 ordinary shares were withheld by the issuer to cover tax withholding obligations related to restricted share unit vesting, at a price of $24.57 per share.
• On February 2, 2026, Hussain acquired 60,000 Restricted Share Units (RSUs) at a price of $0. Of these, 40,000 RSUs will vest in four equal annual installments starting February 2, 2027, and 20,000 RSUs will vest entirely on February 2, 2027.
• Additionally, on February 2, 2026, Hussain was granted 160,000 share options with an exercise price of $25.19. These options will vest in 48 equal monthly installments, beginning March 2, 2026, and have an expiration date of February 2, 2036.
• Following these transactions, Hussain directly beneficially owns 117,645 ordinary shares and 160,000 share options, with an additional 5,500 ordinary shares indirectly owned by a spouse.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mixed but generally neutral filing. While insider sales can sometimes raise concerns, the significant grants of new restricted share units and stock options indicate continued long-term incentive alignment for the Chief Legal Officer.

Positives

• Acquisition of 60,000 Restricted Share Units (RSUs) at a price of $0, aligning executive interests with long-term company performance.
• Grant of 160,000 share options with an exercise price of $25.19, providing a significant incentive for future share price appreciation.
• The vesting schedules for both RSUs (starting February 2, 2027) and share options (starting March 2, 2026, over 48 months) demonstrate a commitment to long-term executive retention and performance.

Negatives

• Sales of a total of 39,961 ordinary shares by the Chief Legal Officer, which could be interpreted as a reduction in direct equity exposure, although often part of pre-planned liquidity events.
• 7,780 ordinary shares were withheld for tax obligations, representing a reduction in directly held shares.

Future Outlook

The filing indicates future vesting events for the Chief Legal Officer's equity awards. 40,000 Restricted Share Units (RSUs) will vest in four equal annual installments starting February 2, 2027, and another 20,000 RSUs will vest fully on February 2, 2027. Additionally, 160,000 share options will vest in 48 equal monthly installments, commencing March 2, 2026, and are exercisable until February 2, 2036.

Industry Context

StockSavvy.ai notes that insider transactions, particularly sales, are closely watched by investors for signals about management's confidence, though often these are part of pre-arranged plans (Rule 10b5-1). The grant of new equity awards is a common compensation practice in the biotech industry to align executive interests with shareholder value and incentivize long-term performance.

Comparison to Industry Standards

• Insider sales and grants of equity awards are standard compensation practices across the pharmaceutical and biotechnology sectors.
• Companies like Pfizer, Moderna, and AstraZeneca frequently use similar equity-based incentives for their executives.
• The vesting schedules (multi-year for RSUs and monthly for options) are typical for long-term incentive plans designed to retain talent and encourage sustained performance.

Stakeholder Impact

• Shareholders might observe the insider sales and new equity grants as part of executive compensation and alignment with company performance.

Next Steps

• First monthly vesting installment for 160,000 Share Options begins on March 2, 2026.
• First annual vesting installment for 40,000 RSUs begins on February 2, 2027.
• 20,000 RSUs vest fully on February 2, 2027.

Key Dates

Recommendation

The filing details routine insider transactions, including both sales (likely for liquidity or tax purposes, potentially under a 10b5-1 plan) and significant grants of new equity awards. These actions do not fundamentally alter the investment thesis for Centessa Pharmaceuticals plc, suggesting a 'hold' recommendation as the core business outlook remains unchanged by these compensation-related disclosures.

Keywords

Centessa Pharmaceuticals, CNTA, Insider Trading, Form 4, Stock Options, Restricted Share Units, Equity Awards, Executive Compensation